Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLC5513 and QL1706 in Advanced Solid Tumors
NCT07272590Phase 2Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of QLC5513 in metastatic solid tumors, sponsored by Qilu Pharmaceutical. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
QLC5513
03
Conditions
metastatic solid tumors
Beyond the preview
Go deeper on NCT07272590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07272590.